AndrewJayLewinMD

PubMed

• 3 citations
  Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Ca...
  Christof M. Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew Lewin, William H. Landschulz, Mark A. Deeg, D...> ;Diabetes Care. 2017 Apr 18
• 5 citations
  Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week P...
  Christof M. Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew Lewin, William H. Landschulz, Mark A. Deeg, D...> ;Diabetes Care. 2016 Nov 1
• 136 citations
  Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
  Christof M. Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew Lewin, William H. Landschulz, Mark A. Deeg, D...> ;Diabetes Care. 2016 Jul 1
• 549 citations
  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
  Melanie J. Davies, Richard M. Bergenstal, Bruce W. Bode, Robert F. Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine B. Jensen, Ralph A. DeFronzo> ;JAMA. 2015 Aug 18
• 1 citations
  Erratum: Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. (Diabetes care (201...
  Ralph A. DeFronzo, Andrew Lewin, Sanjay R. Patel, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle, Uli C. Broedl> ;Diabetes Care. 2015 Jun 1
• 1 citations
  Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402.
  Andrew Lewin, Ralph A. DeFronzo, Sanjay R. Patel, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle, Uli C. Broedl> ;Diabetes Care. 2015 Jun 1
• 2 citations
  Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus
  Andrew J Lewin, Juan P Frías> ;Expert Opinion on Pharmacotherapy. 2015 Mar 6
• 149 citations
  Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
  Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle, Uli C. Broedl> ;Diabetes Care. 2015 Mar 1
• 227 citations
  Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
  Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans-Juergen Woerle, Uli C. Broedl> ;Diabetes Care. 2015 Mar 1
• 13 citations
  Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results
  Sverre E. Kjeldsen, Domenic A. Sica, Hermann Haller, Gloria Cha, Blas Gil-Extremera, Peter Harvey, Frank Heyvaert, Andrew J. Lewin, G. Villa, Giuseppe Mancia> ;Journal of Hypertension. 2014 Dec 1
• 9 citations
  Triple-Combination Treatment with Olmesartan Medoxomil/ Amlodipine/ Hydrochlorothiazide in Hispanic/Latino Patients with Hypertension: The TRINITY Study
  Andrew J. Lewin, Dean J. Kereiakes, Steven G. Chrysant, Joseph L. Izzo, Suzanne Oparil, James Lee, Victor Fernandez, Michael Melino> ;Ethnicity & Disease. 2014 Feb 1
• 13 citations
  Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment:
  Janet B. McGill, Anthony H. Barnett, Andrew J Lewin, Sanjay Patel, Dietmar Neubacher, Maximilian von Eynatten, Hans-Juergen Woerle> ;Diabetes & Vascular Disease Research. 2014 Jan 1
• 8 citations
  Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age
  Andrew J. Lewin, Joseph L. Izzo, Michael Melino, James Lee, Victor Fernandez, Reinilde Heyrman> ;Drugs & Aging. 2013 Apr 3
• 7 citations
  Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial.
  Andrew J. Lewin, Henry Punzi, Xiaohui Luo, Manfred Stapff> ;Clinical Therapeutics. 2013 Feb 1
• 41 citations
  Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, ra...
  Andrew J. Lewin, Lisa Arvay, Dacheng Liu, Sanjay Patel, Maximilian von Eynatten, Hans-Juergen Woerle> ;Clinical Therapeutics. 2012 Sep 1
• 4 citations
  Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial
  Andrew Lewin, Kenneth C. Lasseter, Fang Dong, John C. Whalen> ;Journal of the American Society of Hypertension. 2012 May 1
• 6 citations
  A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.
  Steven G. Terra, V. Somayaji, S. Schwartz, A. J. Lewin, J. G. Teeter, Haiqing Dai, Tu T. Nguyen, R. A. Calle> ;Experimental and Clinical Endocrinology & Diabetes. 2011 Apr 6
• 93 citations
  Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, ...
  Bernard Zinman, Greg Fulcher, Paturi V Rao, Nihal Thomas, Lars Endahl, Thue Johansen, Rebecka Lindh, Andrew Lewin, Julio Rosenstock, Michel Pinget, Chantal Mathieu> ;Lancet. 2011 Mar 12
• 14 citations
  Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial.
  Henry Punzi, Andrew Lewin, Tatjana Lukic, Thomas Goodin, Wei Chen> ;Therapeutic Advances in Cardiovascular Disease. 2010 Nov 18
• 71 citations
  Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfony...
  Richard M. Bergenstal, Andrew Lewin, Timothy L. Bailey, Denise Chang, Titus Gylvin, Victor L. Roberts> ;Current Medical Research and Opinion. 2009 Sep 29
• 630 citations
  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-...
  Bernard Zinman, John E. Gerich, John B. Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde> ;Diabetes Care. 2009 Jul 1
• 15 citations
  Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
  Roopal Thakkar, Moti L. Kashyap, Andrew J. Lewin, Scott Krause, Ping Jiang, Robert J. Padley> ;American Journal of Cardiovascular Drugs. 2009 Jan 1
• 6 citations
  Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status...
  Andrew J. Lewin, Matthew R. Weir> ;Clinical Therapeutics. 2008 Dec 1
• 7 citations
  Efficacy and Safety of a Potent and Selective Peroxisome Proliferator Activated Receptor Alpha Agonist in Subjects With Dyslipidemia and Type 2 Diabetes Mellitus
  Steven G. Terra, Omar L. Francone, Charles F. Contant, Xiang Gao, Andrew J. Lewin, Tu T. Nguyen> ;The American Journal of Cardiology. 2008 Aug 15
• 15 citations
  Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicent...
  Andrew J. Lewin, Robert Lipetz, Jacqueline Wu, Sherwyn Schwartz> ;Clinical Therapeutics. 2007 May 1
• Join now to see all